Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Nanoviricides
(AMEX:NNVC)
Intraday
$1.1018
-0.0082
[-0.74%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$1.1018
-0.0082
[-0.74%]
Last update: 2:57PM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Nanoviricides Stock (AMEX:NNVC)
Nanoviricides Stock (AMEX: NNVC)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, February 16, 2024
EF Hutton Reiterates Buy on Nanoviricides, Maintains $6.5 Price Target
Benzinga Newsdesk
-
Feb 16, 2024, 7:14AM
Thursday, February 15, 2024
Nanoviricides Q2 EPS $(0.18) Down From $(0.15) YoY; As Of December 31, 2023, We Had Cash And Cash Equivalent Current Assets Balance Of Approximately $5.31M. Additional Agreements Have Resulted In A Further Approximately $2.5M Available Cash
Benzinga Newsdesk
-
Feb 15, 2024, 6:44AM
Thursday, February 01, 2024
NanoViricides Explains That The Demonstration Of Strong Safety And Tolerability Of NV-COV-2 Oral Drug Products Has Implications Beyond COVID
Benzinga Newsdesk
-
Feb 1, 2024, 6:26AM
Wednesday, January 31, 2024
A New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?
Meg Flippin
-
Sponsored
Monday, January 29, 2024
NanoViricides Says The Healthy Subjects Part Of The Phase 1a/1b Clinical Trial Of NV-CoV-2 Was Completed Successfully And No Adverse Events Were Reported In Any Of The Ascending Dose Cohorts
Benzinga Newsdesk
-
Jan 29, 2024, 6:33AM
Monday, January 08, 2024
NanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase™ 2024
Kenneth Adams
-
Jan 8, 2024, 8:50AM
Tuesday, November 28, 2023
NanoViricides Has Completed The Single-ascending Dose Part Of The Phase 1A/1B Human Trial Of NV-COV-2, A Broad-spectrum Antiviral Drug, Recruitment For The Multiple-ascending Dose Part Was Also Completed
Benzinga Newsdesk
-
Nov 28, 2023, 6:47AM
Tuesday, September 26, 2023
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
David Willey
-
Sponsored
Monday, September 18, 2023
First Human Clinical Trials Of A Potentially "Game-Changing Broad Spectrum Antiviral" Are Progressing Successfully – Drug Could Treat COVID, RSV And Many Other Respiratory Viruses
Rachael Green
-
Sponsored
Tuesday, August 22, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Aug 22, 2023, 1:31PM
Monday, August 21, 2023
NanoViricides shares are trading higher after the company announced progress for the Phase 1a/1b Human Clinical Trial of NV-CoV-2.
Benzinga Newsdesk
-
Aug 21, 2023, 11:02AM
Nanoviricides Reported That The Phase 1a/1b Human Clinical Trial Of NV-CoV-2, The Company's Broad-spectrum Antiviral Drug, Is Progressing Successfully
Benzinga Newsdesk
-
Aug 21, 2023, 6:52AM
Tuesday, July 18, 2023
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
David Willey
-
Sponsored
Tuesday, July 11, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Jul 11, 2023, 1:37PM
Why Are NanoViricides Shares Gaining Today
Vandana Singh
-
Jul 11, 2023, 12:51PM
NanoViricides shares are trading higher after the company reported effectiveness of antiviral drug candidate in animal model with respiratory syncytial virus infection.
Benzinga Newsdesk
-
Jul 11, 2023, 12:18PM
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Jul 11, 2023, 8:33AM
NanoViricides Reports Effectiveness Of Antiviral Clinical Drug Candidate NV-387 In An Animal Model Of Lethal Lung Infection With Respiratory Syncytial Virus
Benzinga Newsdesk
-
Jul 11, 2023, 6:50AM
Monday, July 10, 2023
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?
David Willey
-
Sponsored
Thursday, July 06, 2023
NanoViricides Says Clinical Trial Of Broad-Spectrum Antiviral Drug NV-CoV-2 Is Progressing Well - NV-CoV-2 Is Positioned To Fulfill Many Unmet Medical Needs
Happy Mohamed
-
Jul 6, 2023, 10:35AM
NanoViricides Says Clinical Trial Of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Is Progressing Satisfactorily
Benzinga Newsdesk
-
Jul 6, 2023, 6:46AM
Wednesday, July 05, 2023
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
David Willey
-
Sponsored
Friday, June 02, 2023
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
Jun 2, 2023, 9:07AM
Thursday, June 01, 2023
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Jun 1, 2023, 1:31PM
EF Hutton Assumes Nanoviricides at Buy, Announces Price Target of $5.25
Benzinga Newsdesk
-
Jun 1, 2023, 4:44AM
Tuesday, May 16, 2023
NanoViricides Says Clinical Trials Of Broad-Spectrum COVID Drug About To Begin
Benzinga Newsdesk
-
May 16, 2023, 6:48AM
Tuesday, April 25, 2023
NanoViricides is Expanding its Broad-Spectrum Antiviral Program To Explore Further Antiviral Applications Of Its COVID Clinical Drug Ingredient
Charles Gross
-
Apr 25, 2023, 6:49AM
Tuesday, April 18, 2023
EF Hutton Reiterates Buy on Nanoviricides, Maintains $5.25 Price Target
Benzinga Newsdesk
-
Apr 18, 2023, 7:44AM
Monday, April 17, 2023
NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate
Charles Gross
-
Apr 17, 2023, 6:47AM
Friday, April 07, 2023
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Apr 7, 2023, 1:31PM
Thursday, April 06, 2023
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Apr 6, 2023, 1:31PM
Tuesday, April 04, 2023
Nanoviricides shares are trading higher after the company announced it executed a license agreement with Karveer Meditech. Under this Agreement, Karveer has the right to commercialize the company's COVID drugs NV-CoV-2 and NV-CoV-2-R in India.
Benzinga Newsdesk
-
Apr 4, 2023, 3:05PM
Nanoviricides Has Executed A License Agreement With Karveer Meditech Pvt. Ltd Based In India, To Commercialize The Company's COVID Drugs In India
Benzinga Newsdesk
-
Apr 4, 2023, 7:47AM
Wednesday, March 08, 2023
With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat – NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It, And To Prepare For Battling Against The Next Likely Coronavirus Pandemic
David Willey
-
Sponsored
Tuesday, February 28, 2023
uniQure To Rally Around 162%? Here Are 10 Other Analyst Forecasts For Tuesday
Lisa Levin
-
Feb 28, 2023, 8:53AM
EF Hutton Maintains Buy on Nanoviricides, Lowers Price Target to $5.25
Benzinga Newsdesk
-
Feb 28, 2023, 4:44AM
Thursday, October 27, 2022
This Company Is Looking For A Monkeypox Drug As City Investigates Deaths
David Willey
-
Sponsored
Thursday, August 18, 2022
Watching NanoViricides Shares As Traders Circulate Article 'Nanotechnology-based strategies against SARS-CoV-2 variants'
Bill Haddad
-
Aug 18, 2022, 1:56PM
Wednesday, August 10, 2022
Monkeypox Is Popping Up In Places It Shouldn't But NanoViricides Says It May Have A Solution
Rachael Green
-
Sponsored
Tuesday, August 09, 2022
NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug Strategy -
Charles Gross
-
Aug 9, 2022, 6:47AM
Friday, August 05, 2022
Short Volatility Alert: NanoViricides, Inc.
Christopher Sappo
-
Aug 5, 2022, 12:23PM
NanoViricides Initiates New Drug Development To Combat Monkeypox Virus
Kenneth Adams
-
Sponsored
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday
Lisa Levin
-
Aug 5, 2022, 6:12AM
Thursday, August 04, 2022
Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
-
Aug 4, 2022, 1:12PM
Ten Stocks Trending on Discord for Thursday August 4, 2022: NVIV, COIN, APDN, STAF, NNVC, AMC, NERV, TSLA, AWX, CCXI
Charles Gross
-
Aug 4, 2022, 11:12AM
NanoViricides shares are trading higher after the company announced it has begun drug development to combat Monkeypox virus.
Benzinga Newsdesk
-
Aug 4, 2022, 10:16AM
NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus
Charles Gross
-
Aug 4, 2022, 6:46AM
Wednesday, May 25, 2022
NanoViricides Patents Its Antiviral Nanotechnology for COVID-19, Continuing Its Development of Potentially Broad-Spectrum Drugs That Are Expected To Be Effective Even Against Emerging Variants
Rachael Green
-
Sponsored
Tuesday, May 24, 2022
58 Biggest Movers From Yesterday
Lisa Levin
-
May 24, 2022, 5:29AM
Monday, May 23, 2022
30 Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
May 23, 2022, 12:11PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch